Back

Cardiac amyloidosis and heart failure phenotypes: a prognostic study of systolic function markers

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Mechanisms of heart failure: emerging evidence Systolic Ventricular Dysfunction ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Amira Zaroui

University Hospital Henri Mondor, Creteil (France)

5 More presentations in this session

Presentation thumbnail
The impact of left ventricular reverse remodeling on asymptomatic structual heart disease
Doctor K. Tanaka (Niigata, JP)
Abstract Slides Video
Presentation thumbnail
Proteomic profiling of circulating exosome identifies CAPG as a key molecule associated with clinical outcomes in heart failure
Doctor S. Okochi (Fukushima, JP)
Abstract Slides Video
Presentation thumbnail
Impact of obesity and breathlessness on MACE outcomes within HFpEF: results from the UK Biobank
Doctor M. Mahmod (Oxford, GB)
Abstract Slides Video
Presentation thumbnail
Mismatch between lead I from the 12-Lead ECG and smartwatch ECG: can AI models adapt for left ventricular systolic dysfunction prediction?
Mr J. Jang (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Identification of biomarkers for right ventricular dysfunction in dilated cardiomyopathy using urinary proteomics and machine learning
Doctor J. Zhang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Mechanisms of heart failure: emerging evidence
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
FLAT-ATTR: A fully automated machine learning algorithm to track disease progression in ATTR-CM
thumbnail
Congress Presentation
Improvement of ventricular dysfunction in transthyretin cardiac amyloidosis after short-term treatment with Tafamidis - Strain can be the best monitoring tool?
thumbnail
Congress Presentation
Echocardiographic AMYLI score in systemic light-chain amyloidosis: clinical relevance and risk stratification

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources